CFTR and cystic fibrosis: Moreover, there may be potential to acquire stem cells derived from lungs of CF patients, which were engineered using CRISPR/Cas9 innovative technology to rectify the mutation of CFTR and reinsert them into one of those lung niches where stem cells get their appropriate microenvironment for their growth, development, and survivability (Firth et al., 2015).